Craft

Equillium

Stock Price

$1.5

2024-05-13

Market Capitalization

$54.3 M

2024-05-13

Revenue

$36.1 M

FY, 2023

Equillium Summary

Company Summary

Overview
Equillium is a biotechnology company developing products for autoimmune and inflammatory disorders. It offers Itolizumab, amonoclonal antibody that targets the CD6-ALCAM signaling pathway; EQ101, a tri-specific inhibitor of IL-2, IL-9, and IL-15, three inflammatory cytokines implicated in multiple diseases; EQ102, a selective inhibitor of IL-15 and IL-21 for treatment of gastrointestinal diseases.
Type
Public
Status
Active
Founded
2017
HQ
San Diego, CA, US | view all locations
Website
https://www.equilliumbio.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Bruce Steel

    Bruce Steel, Co-Founder, Chief Executive Officer, Director

  • Jason Keyes

    Jason Keyes, Chief Financial Officer

  • Daniel M. Bradbury

    Daniel M. Bradbury, Co-Founder, Executive Chairman

  • Stephen Connelly

    Stephen Connelly, Co-Founder, Chief Scientific Officer, Director

Operating MetricsView all

Trademarks (US)

2

Q1, 2023

Trademarks (Foreign)

1

Q1, 2023

Facility Space Leased, sq. ft.

1.8K

FY, 2022

LocationsView all

2 locations detected

  • San Diego, CA HQ

    United States

    2223 Avenida De La Playa, Suite 105

  • San Francisco, CA

    United States

    601 Gateway Blvd., Suite 1020

Equillium Financials

Summary Financials

Revenue (Q1, 2024)
$10.7M
Net income (Q1, 2024)
($2.7M)
Cash (Q1, 2024)
$11.6M
EBIT (Q1, 2024)
($2.8M)
Enterprise value
$43.4M

Footer menu